Changes in Beneficial Ownership · 4
Cadrenal Therapeutics, Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-09
- Issuer
- Cadrenal Therapeutics, Inc.
- Issuer CIK
- 0001937993
- Trading symbol
- CVKD
Reporting owner 1
- Name
- Pham Quang X
- Reporting owner CIK
- 0001405290
- Relationship
- Director · Officer · 10% owner
- Officer title
- Chairman and CEO
- Address
- C/O CADRENAL THERAPEUTICS, INC., 822 A1A NORTH, SUITE 306, PONTE VEDRA, FL, 32082
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | 0.91 | 2026-10-09 | A · Form 4 | 200,000[F1] | A | 0 | 2026-10-09[F1] | 2036-10-08 | Common Stock | 200,000 | 200,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Quang X. Pham
- Date
- 2026-10-13
Company context
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. The Company’s pipeline includes CAD-1005, tecarfarin, and frunexian. CAD-1005 is a novel investigational therapeutic in development for the treatment of heparin-induced thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). CAD-1005 is designed to selectively inhibit 12-lipoxygenase (12-LOX), an enzyme central to platelet immune activation and thrombo-inflammatory signaling in HIT. CAD-1005 is intended to be used alongside existing standards of care and is being developed to address the underlying biological mechanisms that drive disease progression. CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration (“FDA”) for prophylaxis of thrombosis in patients with HIT, FDA Fast Track designation for the treatment and prevention of HIT, and an orphan designation from the European Medicines Agency for the treatment of platelet-activating factor 4 disorders. Second-generation 12-LOX oral therapeutics (CAD-2000) are also in development for chronic indications.